The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Related News Articles

Headline
The AHA Dec. 18 filed an amicus brief in the U.S. Court of Appeals for the First Circuit in support of a district court’s dismissal of an online tracking…
Headline
The Assistant Secretary for Technology Policy has issued new FAQs regarding information blocking. The updates are intended to provide clarifying…
Headline
The Cybersecurity and Infrastructure Security Agency Dec. 11 released an update to its voluntary Cybersecurity Performance Goals, which includes measurable…
Headline
U.S. and international agencies are warning of potential cyberattacks on health care and other critical infrastructure from state-sponsored cyber actors in…
Headline
John Pastor, president of Fairview Pharmacy Services and chief operating officer of Fairview Pharmacy Solutions, shares how M Health Fairview’s expansive…
Headline
A critical, unauthenticated remote code execution vulnerability known as React2Shell has been added to the Cybersecurity and Infrastructure Security Agency’s…